Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in <i>BRAFV600E</i> -Mutant Pediatric Low-Grade Glioma
Our findings demonstrate that the cost-effectiveness of Dab-Tram is sensitive to price and duration of treatment, with uncertainty related to clinical effectiveness over the life course and optimal treatment duration. In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.
Authors
- Cindy L. Gauvreau
- Liana Nobre (ORCID: https://orcid.org/0000-0001-5900-977X)
- Alan Yang (ORCID: https://orcid.org/0000-0002-0344-6812)
- Bryan Gascon (ORCID: https://orcid.org/0000-0002-5188-9407)
- Avram Denburg (ORCID: https://orcid.org/0000-0003-0039-0742)
- Uri Y. Tabori
- Derek S Tsang
- Julie Bennett
- Petros Pechlivanoglou
- Cynthia Hawkins
Institutions
- University Health Network (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- Princess Margaret Cancer Centre (CA)
- University of Alberta Hospital (CA)
- Public Health Ontario (CA)
- Institute for Clinical Evaluative Sciences (CA)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1200/op-25-01263
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00